[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Louisiana State University Health Sciences Center in New Orleans\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":318},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,80,109,145,172,203,232,267,293],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100637148","periodontal-inflammation-and-epigenetics-in-obese-individuals-100637148",false,"NCT07610902","Periodontal Inflammation and Epigenetics in Obese Individuals","Association Between Epigenetic Changes, Periodontal Microbiota, And Periodontal Inflammation in Obese Individuals","Inclusion Criteria:\n\n* Adults aged ≥18 years,\n* No history of periodontal therapy in the last 6 months,\n* No use of tobacco,\n* No history of pregnancy lactation or contraceptive medication.\n* Need to have a minimum of 20 teeth.\n\nExclusion Criteria:\n\n* Had antimicrobial\u002Fantiviral therapy in the previous 3 months,\n* History of uncontrolled diabetes,\n* History of rheumatoid arthritis,\n* History of osteoporosis,\n* History of oral cancer,\n* Currently taking hormonal contraception,\n* If pregnant or lactating currently or prior 6 months,\n* Subjects on current weight loss drugs\n* If planning weight reduction surgery during the time of the study\n* Any other condition, disease or therapy with documented influence on oral inflammation and\u002For oral microbial environment.",true,"ALL","18 Years","75 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this study is to investigate the long-term changes in host epigenetic modifications in obese individuals with periodontitis. The aims of the study are:\n\n• To monitor longitudinal changes in host epigenetic modifiers following non-surgical periodontal therapy in periodontitis patients Study subjects would be categorized into two groups, non-obese with periodontitis, and obese with periodontitis. The study will primarily evaluate changes among these groups cross-sectionally, then longitudinally following non-surgical periodontal therapy (deep cleaning) to determine if any changes occur with treatment.",[28,29],"Obesity","Periodontitis",[28,29,31,32],"Epigenitics","Periodontal inflammation","NOT_YET_RECRUITING","2026-05-20",{"date":36,"type":37},"2026-05-28","ACTUAL",{"date":39,"type":22},"2026-05-25",{"date":41,"type":22},"2026-12-30",{"name":43,"class":44},"Louisiana State University Health Sciences Center in New Orleans","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100640899","multilevel-intervention-for-ldct-lung-cancer-screening-and-smoking-cessation-among-african-americans-100640899","NCT07576595","Multilevel Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African Americans","Effectiveness of a Multilevel Integrated Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African Americans","Inclusion Criteria:\n\n* African American\n* 20+ pack years of smoking\n* eligible for or received LDCT screening\n* current smoker\n* English speaking\n\nExclusion Criteria:\n\n* N\u002FA","50 Years","80 Years",{"count":56,"type":22},250,[25],"This study aims to reduce disparities and the burden of lung cancer among African American smokers by supporting a Multiple-level intervention integrating lung cancer screening and smoking cessation (MILS), followed the NIH DEIA strategies using multilevel interventions that impact determinants of health and address health disparities at appropriate time points across the life course.",[60,61,62],"Lung Cancer Screening","Tobacco Use Disorder","Smoking Cessation",[64,65,60,62,66,67,68,69],"African American","Health Disparities","Tobacco Use","Low-Dose Computed Tomography","LDCT","Behavioral Intervention","RECRUITING","2026-05-07",{"date":73,"type":37},"2026-05-11",{"date":75,"type":37},"2025-04-17",{"date":77,"type":22},"2030-06",{"name":43,"class":44},2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":45},"100630475","improving-health-literacy-in-patients-with-schizophrenia-spectrum-disorder-100630475","NCT07488156","Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder","The Impact of Health Literacy on the Attitudes Toward Pharmacological Treatment in Patients With Schizophrenia Spectrum Disorder","Inclusion Criteria:\n\n* Patients admitted to the University Medical Center-New Orleans (UMCNO) inpatient behavioral health unit ages 18 and older with a new or previous diagnosis of schizophrenia spectrum disorder outside of substance use disorders\n* Patients must be proficient in English.\n* Patients must have a government issued social security number (required for reimbursement through the university).\n\nExclusion Criteria:\n\n* Patients at UMCNO that are ages 17 or younger\n* Patients with SSD and concomitant intellectual disability, as evidenced by prior documented history on chart review or patients suspected to have intellectual disability or impairment based on clinical interactions\n* Patients with concomitant substance use and documentation of psychosis being resolved after a period of washout and without the use of psychotropic medications\n* Patients unable to complete health literacy assessments, attitude towards treatment assessments, and IQ testing due to severity of symptoms during hospitalization\n* Patients that are not proficient in English\n* Patients that do not have a government issued social security number","65 Years",{"count":89,"type":22},34,[25],"The Impact of Health Literacy on the Attitudes toward Pharmacological Treatment in Patients with Schizophrenia Spectrum Disorder\n\nThis interventional study is aimed at:\n\n* assessing and improving the health literacy and\n* assessing the attitude towards treatment of patients with schizophrenia spectrum disorders while they are admitted to the inpatient psychiatric unit.",[93,94,95],"Schizophrenia Disorder","Schizoaffective Disorder","Psychosis",[97,98,99,100],"Educational interventions","Schizophrenia","Schizophrenia spectrum disorders","Health literacy","2026-03-17",{"date":103,"type":37},"2026-03-23",{"date":105,"type":22},"2026-03-01",{"date":107,"type":22},"2028-01-01",{"name":43,"class":44},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":45},"100628525","phase-1-precision-microbiota-interventions-for-senoreduction-trial-100628525","NCT07462767","Precision Microbiota Interventions for Senoreduction Trial","Geroprotective Precision Medicine Strategies in PWH That Use Alcohol","PreMIS","Inclusion Criteria:\n\n* Age ≥40 years\n* People with HIV\n* Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG)\n\nExclusion Criteria:\n\n* Probiotic use in past 3 months\n* Recent antibiotics or immunosuppressives\n* Allergy to study products\n* Pregnancy or breastfeeding\n* Inability to comply","40 Years",{"count":119,"type":22},160,[121,122],"PHASE1","PHASE2","People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.",[125,126,127,128],"HIV Infections","Alcohol Drinking","Aging","Immunosenescence",[130,131,128,132,133,134,135,136],"People with HIV","Alcohol use","Senescence","Microbiome","Probiotic","Blueberry extract","Crossover trial","2026-03-05",{"date":139,"type":37},"2026-03-10",{"date":141,"type":22},"2026-04-01",{"date":143,"type":22},"2029-12-01",{"name":43,"class":44},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":45},"100614489","phase-4-clinical-performance-of-nobel-n1-system-100614489","NCT07280260","Clinical Performance of Nobel N1 System","Effects of Early Loading Protocol on the Survival of the Nobel N1 Implant System: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Males and females, age 18 or older\n\n  * Can provide an Informed Consent in English.\n  * Absence of a single posterior tooth in mandible or maxilla with presence of natural neighboring teeth (except for second molar which only requires presence of first molar)\n  * Presence of antagonist teeth\n  * Possibility and will for an immediate restoration.\n  * Systemic health recorded as an American Society of Anesthesiologists (ASA) I or II\n\nExclusion Criteria:\n\n* · Unavailability to attend the follow-up visits.\n\n  * A systemic contraindication for oral surgical procedures; ASA III or IV.\n  * Pregnancy or nursing on screening or before the surgical procedure.\n  * Diseases that could alter healing or bone metabolism (uncontrolled diabetes, diagnostic osteoporosis, etc.),\n  * Taking medications that are altering healing or bone metabolism (bisphosphonates, long-time corticosteroids intake, RANK inhibitors, etc.)\n  * Alcohol or drug abuse.\n  * Current heavy smoking behavior (≥10 cigarettes\u002Fday).\n  * Radiation therapy to the head or neck region.\n  * Pathology in the implant planned sites that prevent implant placement.\n  * Current diagnosis of Diabetes, which is uncontrolled (\\>7 HbA1C).\n  * Need for sinus lift or vertical bone augmentation\n  * Previously failed implant site",{"count":153,"type":22},50,[155],"PHASE4","The purpose of the study is to evaluate whether N1 dental implants are successful when a final crown is placed on them at 6 weeks from implant placement surgery.",[158,159],"Tooth Loss","Dental Implant",[161,162,163],"Tooth loss","Edentulous","Dental implants","2025-12-11",{"date":166,"type":37},"2025-12-12",{"date":168,"type":22},"2025-12-15",{"date":170,"type":22},"2028-01-30",{"name":43,"class":44},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":191,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":45},"100459767","phase-4-immunogenicity-of-gardasil-9-hpv-vaccine-in-people-living-with-hiv-100459767","NCT05266898","Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV","Prospective Observational Immunogenicity Trial of Gardasil-9 HPV Vaccine in People Living With Adequately Managed HIV","AGO-Gard","Inclusion Criteria:\n\n* HIV seropositive\n* immune intact (CD4+ T cell count in peripheral blood \\>200 cells\u002Fml)\n* HIV controlled (peripheral blood HIV viral load \\\u003C1,000 genome copies\u002FmL)\n* Stable on antiretroviral regimen for ≥3 months\n* Gardasil-9 naive and age ≤45 OR\n* documented receipt of 3 doses of Gardasil-4 or Gardasil-9 HPV vaccine\n\nExclusion Criteria:\n\n* Medical contraindication for vaccination (vaccine-naive arm only)\n* Women who are pregnant\n* Acute illness\n* Taking chronic steroids, \\>0.5mg\u002Fkg prednisone or equivalent\n* Taking immune modulating medications\n* Received blood transfusion\u002Fblood products within the past 6 months\n* Recipients of other vaccine products within the past month\n* Inability to provide informed written consent",{"count":56,"type":22},[155],"The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection.\n\nThe secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series, and to determine the protection afforded by Gardasil vaccine over time in previously vaccinated adults living with HIV.\n\nThe clinical hypothesis is that adults with virologically controlled HIV mount a serum antibody response to the nonavalent HPV vaccine that is comparable to HIV negative counterparts. We also postulate that HPV vaccination will provide short-term clinical benefit against HPV infections and disease associated with vaccine genotypes and continuing protection against vaccine genotypes of HPV over time.",[184,185,186,187,188,189,190],"Papillomavirus Vaccines","Human Immunodeficiency Virus","Papillomavirus Infection","Serology","Cervical Intraepithelial Neoplasia","Anal Intraepithelial Neoplasia","Oral Cavity Infection",[192,193,194],"Gardasil-9 HPV vaccine","human papillomavirus","human immunodeficiency virus","2025-04-15",{"date":197,"type":37},"2025-04-18",{"date":199,"type":37},"2022-11-30",{"date":201,"type":22},"2026-06",{"name":43,"class":44},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":210,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":45},"100575548","virtual-reality-as-adjunct-therapy-for-vaso-occlusive-pain-100575548","NCT06773715","Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain","Changing the View of Pain: Using Virtual Reality As Adjunctive Therapy for Sickle Cell Pain in Pediatric Patients","Inclusion Criteria:\n\n1. Patient ≥ 8 up to 21 years of age\n2. Presenting to CHNOLA ER or outside facility with chief complaint of vaso-occlusive pain crisis, requiring inpatient admission for further pain management\n3. No known cognitive or neurological deficits\n4. Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n\nExclusion Criteria:\n\n1. Patients aged 7-years-old and younger.\n2. Patents upon admission found to have sequela of their sickle cell disease that would require medical therapy greater than the standard of care for a vaso-occlusive pain event. This includes acute chest syndrome, splenic sequestration, post-operative pain, and\u002For cerebrovascular accident\n3. Patients who are developmentally or cognitively incapable of using VR equipment and answering questions appropriately\n4. Failure to obtain or refusal to provide parental\u002Fguardian permission (informed consent) and if appropriate child assent\n5. Patient has previously participated in the study\n6. Study team is unable to initiate study interventions within the first 24 hours of a patient's admission","8 Years","21 Years",{"count":213,"type":22},36,[25],"The goal of this randomized control clinical trial is to learn if virtual reality can be used to treat sickle cell pain in children. The main questions it aims to answer are:\n\nDoes virtual reality reduce pain severity during a child's hospital stay for a vaso-occlusive pain crisis?\n\nDoes virtual reality decrease the daily use of opiates?\n\nResearchers will compare standard therapy to the use of standard therapy plus a daily virtual reality experience to see if virtual reality works to treat sickle cell pain.\n\nAll patients will:\n\n\\- Be asked to fill out a pain assessment survey three times daily for up to 3 days\n\nIf randomized to intervention arm, patients will:\n\n* Participate in an immersive virtual reality experience once daily for up to 3 days\n* Fill out a survey twice daily to monitor for side effects from virtual reality experience\n* Fill out a satisfaction survey once during the study period",[217,218],"Sickle Cell Disease","Vaso-occlusive Pain Episodes",[220,221,222,223],"virtual reality","adjunctive therapy","opiate consumption","pain reduction","2025-01-13",{"date":226,"type":37},"2025-01-14",{"date":228,"type":37},"2024-09-12",{"date":230,"type":22},"2025-12-19",{"name":43,"class":44},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":239,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":249,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":45},"100553217","optimal-injection-interval-for-intra-detrusor-botulinum-toxin-100553217","NCT06483217","Optimal Injection Interval for Intra-Detrusor Botulinum Toxin","Optimal Injection Interval for Intra-Detrusor Botulinum Toxin: A Randomized Controlled Trial Utilizing a Patient-Centered Approach","Inclusion Criteria:\n\n* diagnosis of overactive bladder, detrusor overactivity, urinary urgency, urinary frequency, nocturnal polyuria, or urge urinary incontinence\n* pursuing treatment with intravesical botulinum toxin injections\n\nExclusion Criteria:\n\n\\- non-OAB diagnosis such as pelvic pain or interstitial cystitis","FEMALE",{"count":241,"type":22},100,[25],"The goal of this clinical trial is to see if patients deciding their own follow up times can increase the effectiveness of botulinum toxin (BTX or \"Botox\") injection for overactive bladder (OAB). The main questions it aims to answer are:\n\n* Does the time between repeat injections differ from the 6-month standard when it is based on patient symptoms alone?\n* Does symptom control or patient satisfaction change when patients control their own follow up times?\n\nParticipants will undergo standard botulinum toxin injection into the bladder for OAB treatment and will then be randomly assigned to follow up either at a standard 6-month interval or whenever they feel their symptoms return.",[245,246,247,248],"Overactive Bladder","Urinary Urgency","Urinary Incontinence","Urge Urinary Incontinence",[250,251,252,253,254,255,256,257,258],"intradetrusor botulinum toxin","intravesical botox","intradetrusor botox","bladder chemodenervation","botox","chemodenervation","overactive bladder","urge urinary incontinence","intravesical botulinum toxin","2024-07-15",{"date":261,"type":37},"2024-07-17",{"date":263,"type":22},"2024-07",{"date":265,"type":22},"2025-10",{"name":43,"class":44},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":282,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":45},"100490250","phase-4-does-topical-ophthalmic-proparacaine-05-prior-to-probing-and-irrigation-decrease-pain-100490250","NCT05663684","Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?","Does Administration of Proparacaine Hydrochloride 0.5% Ophthalmic Solution Prior to Canalicular Probing and Irrigation Decrease Patient Discomfort?","Inclusion Criteria:\n\n* Participants of any sex aged 18 years or older\n* Signs and symptoms of epiphora which necessitate performance of a diagnostic probing and irrigation of the bilateral lower eyelid lacrimal drainage system at Louisiana State University Health Sciences Center or any of the listed physician offices who present with a complaint of epiphora from either eye\n\nExclusion Criteria:\n\n* A known allergy to topical proparacaine hydrochloride\n* Known pre-existing scarring, surgery, radiation to the nasolacrimal system\n* Presence of blockage and or reflux on probing and irrigation of either side\n* Cognitive Impairment",{"count":275,"type":22},145,[155],"Purpose: It is unknown whether instillation of a drop of anesthetic ophthalmic solution into the eye such as proparacaine hydrochloride 0.5% prior to probing and irrigation of the tear duct (lacrimal drainage) system improves participant comfort during the procedure. To date, there have been no formal studies evaluating the possible benefit of this pretreatment.\n\nMethods: Participants 18 years and older who present to the Louisiana State University or associated outpatient ophthalmology clinic(s) with a complaint of epiphora (excessive tearing) who necessitate bilateral lower lid probing and irrigation of the lacrimal drainage system will be enrolled in the study. One eye will be randomized to receive a drop of the anesthetic Proparacaine hydrochloride 0.5% and the other eye will receive a control drop of Balanced Salt Solution (BSS). Probing and irrigation will then be performed in the usual fashion. The participant will then be questioned via survey on a pain scale of 1-5 as to the amount of subjective pain experienced on each side during the procedure.\n\nExpected Results: Investigators expect participants will experience statistically significantly less pain in eyes that have received a drop of Proparacaine hydrochloride 0.5% prior to performance of probing and irrigation compared to the eyes which have received the control drop.",[279,280,281],"Epiphora","Dacryostenosis","Dacryocystitis",[283,284],"Nasolacrimal duct obstruction","Probe and irrigation","2022-12-15",{"date":287,"type":37},"2022-12-23",{"date":289,"type":37},"2020-06-30",{"date":291,"type":22},"2023-01-31",{"name":43,"class":44},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":45},"100306469","new-orleans-pulmonary-hypertension-biobank-100306469","NCT03269630","New Orleans Pulmonary Hypertension Biobank","NO-PH Biobank","Inclusion Criteria:\n\n* Diagnosis of pulmonary hypertension and followed at the Comprehensive Pulmonary Hypertension Center OR\n* Diagnosis of systemic sclerosis and followed at the Comprehensive Pulmonary Hypertension Center OR\n* Diagnosis of mixed connective tissue disease and followed at the Comprehensive Pulmonary Hypertension Center OR\n* Undergoing outpatient right heart catheterization\n\nExclusion Criteria:\n\n* Age\\\u003C18\n* Pregnant\n* Unable to understand English\n* Currently incarcerated\n* Unwilling or unable to sign informed consent",{"count":301,"type":22},450,"OBSERVATIONAL","Pulmonary hypertension (PH) is a serious condition characterized by a mean pulmonary artery pressure \\>=25mmHg on right heart catheterization (RHC). Despite advances in PH care, outcomes are still sub-optimal and further research is required into the pathobiology of the disease and development of biomarkers that can guide clinical care. The investigators are establishing a biobank to collect samples (blood, urine, stool) from patients with pulmonary hypertension, patients at high risk for pulmonary hypertension, healthy controls, and patients undergoing right heart catheterization. Specimens will be stored for future investigations.",[305,306,307,308,309],"Pulmonary Hypertension","Systemic Sclerosis","Mixed Connective Tissue Disease","Heart Failure With Normal Ejection Fraction","Healthy","2021-09-09",{"date":312,"type":37},"2021-09-10",{"date":314,"type":37},"2017-12-29",{"date":316,"type":22},"2027-10",{"name":43,"class":44},""]